天坛生物：关于下属企业药品临床试验进展的公告

Group 1 - The core point of the article is that Tiantan Biological has announced the completion of Phase I clinical trials for its "Recombinant Human Coagulation Factor VIII-Fc Fusion Protein" developed by its subsidiary Chengdu Rongsheng Pharmaceutical [2] Group 2 - The clinical trial summary report has been obtained following the completion of the Phase I clinical trial [2]